


We Claim:

1. 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride **1**



x HCl **1.**

2. The compound according to claim 1, wherein the compound is present in the form of one of its hydrates.
3. The compound according to claim 1, wherein the compound is present in the form of its monohydrate.
4. The compound according to claim 1, wherein the compound is present in the form of its hemihydrate.
5. A pharmaceutical composition comprising:
 - (a) the compound according to claim 1; and
 - (b) a pharmaceutically acceptable excipient.
6. A pharmaceutical composition comprising:
 - (a) the compound according to claim 2; and
 - (b) a pharmaceutically acceptable excipient.
7. A pharmaceutical composition comprising:
 - (a) the compound according to claim 3; and
 - (b) a pharmaceutically acceptable excipient.

8. A pharmaceutical composition comprising:

- (a) the compound according to claim 4; and
- (b) a pharmaceutically acceptable excipient.

9. A method of treating diseases in which inhibition of the cellular Na^+/H^+ exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 1.

10. A method of treating diseases in which inhibition of the cellular Na^+/H^+ exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 2.

11. A method of treating diseases in which inhibition of the cellular Na^+/H^+ exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 3.

12. A method of treating diseases in which inhibition of the cellular Na^+/H^+ exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 4.

13. The method according to claim 9, wherein the compound according to claim 1 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.

14. The method according to claim 10, wherein the compound according to claim 2 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.

15. The method according to claim 11, wherein the compound according to claim 3 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.

16. The method according to claim 12, wherein the compound according to claim 4 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.

1057597-012502